Novo Nordisk shares fall to the final test results for new obesity medication

Unlock the editor’s digestion free

FT editor Roula Khalaf, chooses his favorite stories in this weekly newsletter.

Shares in Novo Nordisk gave a bad result than the expected test results for the latest obesity medicines from Ozempic and Wegovy’s blockbuster treatment manufacturer.

In patients with obese or overweight patients, Cagrisem’s court could not show an open advantage for a drug from the rival Eli Lilly. CAGRISEMA group, 8. After 68 weeks of body weight after 68 weeks, Plasebo, Novo Nordisk, compared to 3.1 percent, Novo Nordisk said.

Novo’s share fell 8 percent on Monday, before Happened in December After testing the late scene of the CAGRISEMA in Obsurge or obese people, the human body lost an average of 22.7 percent. It was only marginalized by the results for Mounjaro, which is the existing opponent treatment prepared by Eli Lilly.

CagRisema was a record of the study of William Blair’s capital, Zepbound, another Lilly medicine, another Lilly medicine was “worse” to surpass.

“We believe that the reading was represented by the best chances of adults living with both obesity and obesity, but also the pity and type diabetes,” he said. “Therefore, we think today’s results are especially disappointed.”

Novo Nordisk remains in line with Cagrisema, a flagship in the lucrative weight market. Chief Executive Lars Frugaard Jørgensen, said the company was “really important”.

The latest results confirmed the superior effectiveness of the CAGRISEMA in people with overweight or obesity and 2 types of diabetes, said, Martin Holst Lange, Novo Nordiskin Vice President for the development of Nordiskin.

The trial examined the effect of a weekly group of 1,200 participants in the 1200 participant group, which is 1,200 participants with a secondary base of 102 kg. Patients were allowed to change drugs, 61.9 percent of them, the maximum dose of testing ended.

Almost 90 percent of Cagrisema patients managed to lose 5 percent or more compared to 30 percent in placebo.

According to Evan David Seigerman, the results are leaving the company, Semaglutide, Ozemmlutide, Ozempic and Wegovy after active ingredients.

“Today’s reading continues to put pressure on the story for Shares, as investors are looking to clear the way to the company’s semaglutide,” he said.